I think the best thing is to average out the analyst's estimates which will put us at around $21/share. Then, watch for presentations and releases that will give us more insights into the data and that may form a clearer picture of how Arikace fits into the CF therapy universe. I suspect that we will find that it has a place as a top 3 product. If so, the analysts will upgrade and reset their target prices. And, NTM is clearly a very large opportunity that some of the analysts believe is the real driver here..